Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
β-lactam Antibiotics
100%
Cefiderocol
100%
Beta-lactams
100%
Difficult-to-treat Pseudomonas Aeruginosa
100%
Difficult-to-treat
80%
MDR-PA
80%
Ceftolozane/tazobactam
80%
Carbapenemase-producing
60%
β-lactamase Inhibitor
40%
Xeruborbactam
40%
Inhibitor Combination
40%
Cefepime-taniborbactam
40%
KPC-2
20%
In Vitro Activity
20%
Hospitalized Patients
20%
Whole Genome Sequencing
20%
Minimum Inhibitory Concentration
20%
BlaGES
20%
Producing Strain
20%
Resistance Phenotypes
20%
β-lactamase
20%
Bloodstream
20%
Pseudomonas Aeruginosa Infection
20%
Carbapenemase Genes
20%
Triplicate
20%
Blimp-1
20%
Carbapenemases
20%
Broth Microdilution
20%
Intra-abdominal Infection
20%
Ceftazidime-avibactam
20%
Pseudomonas Aeruginosa Isolates
20%
Imipenem-relebactam
20%
BlaVIM
20%
Tertiary Care Centers
20%
Susceptibility Profile
20%
Medicine and Dentistry
Pseudomonas aeruginosa
100%
Lactam
100%
β-Lactam antibiotic
100%
Cefiderocol
100%
Carbapenemase
100%
Cefepime
100%
Beta-Lactamase
80%
Penicillinase
60%
Zidebactam
60%
In Vitro
20%
Tertiary Care
20%
Whole Genome Sequencing
20%
Urinary System
20%
Relebactam
20%
Pseudomonas Infection
20%
Imipenem
20%
Abdominal Infection
20%
Avibactam Plus Ceftazidime
20%
Tazobactam
20%
Ceftolozane
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pseudomonas aeruginosa
100%
Lactam
100%
Beta Lactam Antibiotic
100%
Carbapenemase
100%
Cefiderocol
100%
Cefepime
100%
Penicillinase
60%
Zidebactam
60%
Minimum Inhibitory Concentration
20%
Relebactam
20%
Imipenem
20%
Pseudomonas Infection
20%
Tazobactam
20%
Avibactam Plus Ceftazidime
20%
Ceftolozane
20%
Abdominal Infection
20%
Immunology and Microbiology
Pseudomonas aeruginosa
100%
Cefiderocol
100%
Susceptibility
60%
Infectious Disease
40%
Infection
40%
Minimum Inhibitory Concentration
20%
Whole Genome Sequencing
20%
Broth Dilution
20%
In Vitro
20%